92 related articles for article (PubMed ID: 25708310)
1. A ruthenium(II) complex inhibits tumor growth in vivo with fewer side-effects compared with cisplatin.
Wang JQ; Zhang PY; Ji LN; Chao H
J Inorg Biochem; 2015 May; 146():89-96. PubMed ID: 25708310
[TBL] [Abstract][Full Text] [Related]
2. Combination of ruthenium (II) polypyridyl complex Δ-Ru1 and Taxol enhances the anti-cancer effect on Taxol-resistant cancer cells through Caspase-1/GSDMD-mediated pyroptosis.
Chen D; Guo S; Tang X; Rong Y; Bo H; Shen H; Zhao Z; Qiao A; Shen J; Wang J
J Inorg Biochem; 2022 May; 230():111749. PubMed ID: 35144218
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds.
Guichard SM; Else R; Reid E; Zeitlin B; Aird R; Muir M; Dodds M; Fiebig H; Sadler PJ; Jodrell DI
Biochem Pharmacol; 2006 Feb; 71(4):408-15. PubMed ID: 16360645
[TBL] [Abstract][Full Text] [Related]
4. Chiral ruthenium(II) complex Δ-[Ru(bpy)
Bai M; Pan T; Yu G; Xie Q; Zeng Z; Zhang Y; Zhu D; Mu L; Qian J; Chang B; Mei WJ; Guan S
Eur J Pharmacol; 2019 Jun; 853():49-55. PubMed ID: 30880177
[TBL] [Abstract][Full Text] [Related]
5. Dual topoisomerase I and II poisoning by chiral Ru(II) complexes containing 2-thiophenylimidazo[4,5-f][1,10]phenanthroline derivatives.
Wang YC; Qian C; Peng ZL; Hou XJ; Wang LL; Chao H; Ji LN
J Inorg Biochem; 2014 Jan; 130():15-27. PubMed ID: 24145066
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, characterization, and anticancer activity of ruthenium(II)-β-carboline complex.
Chen Y; Qin MY; Wu JH; Wang L; Chao H; Ji LN; Xu AL
Eur J Med Chem; 2013; 70():120-9. PubMed ID: 24141202
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, anticancer, and cytotoxic activities of some mononuclear Ru(II) compounds.
Karki SS; Thota S; Darj SY; Balzarini J; De Clercq E
Bioorg Med Chem; 2007 Nov; 15(21):6632-41. PubMed ID: 17765549
[TBL] [Abstract][Full Text] [Related]
9. Chiral ruthenium complexes induce apoptosis of tumor cell and interact with bovine serum albumin.
Yuan F; Chen X; Liu Y; Zhang T; Sun D; Liu J
Chirality; 2012 Feb; 24(2):174-80. PubMed ID: 22180296
[TBL] [Abstract][Full Text] [Related]
10. [Ru(phen)
Li R; Ma Y; Hu X; Wu W; Wu X; Dong C; Shi S; Lin Y
Dalton Trans; 2020 Jul; 49(26):8864-8871. PubMed ID: 32602487
[TBL] [Abstract][Full Text] [Related]
11. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
12. A novel phenotype-based approach for systematically screening antiproliferation metallodrugs.
Wang YH; Cheng CC; Lee WJ; Chiou ML; Pai CW; Wen CC; Chen WL; Chen YH
Chem Biol Interact; 2009 Nov; 182(1):84-91. PubMed ID: 19682442
[TBL] [Abstract][Full Text] [Related]
13. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ
J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935
[TBL] [Abstract][Full Text] [Related]
14. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
15. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.
Bergamo A; Gagliardi R; Scarcia V; Furlani A; Alessio E; Mestroni G; Sava G
J Pharmacol Exp Ther; 1999 Apr; 289(1):559-64. PubMed ID: 10087050
[TBL] [Abstract][Full Text] [Related]
16. DNA-binding and photoactivated enantiospecific cleavage of chiral polypyridyl ruthenium(II) complexes.
Zhang QL; Liu JH; Liu JZ; Zhang PX; Ren XZ; Liu Y; Huang Y; Ji LN
J Inorg Biochem; 2004 Aug; 98(8):1405-12. PubMed ID: 15271518
[TBL] [Abstract][Full Text] [Related]
17. DNA binding, cytotoxicity, and apoptotic-inducing activity of ruthenium(II) polypyridyl complex.
Zhang P; Chen J; Liang Y
Acta Biochim Biophys Sin (Shanghai); 2010 Jul; 42(7):440-9. PubMed ID: 20705582
[TBL] [Abstract][Full Text] [Related]
18. Ruthenium (II) polypyridyl complexes stabilize the bcl-2 promoter quadruplex and induce apoptosis of Hela tumor cells.
Wang C; Yu Q; Yang L; Liu Y; Sun D; Huang Y; Zhou Y; Zhang Q; Liu J
Biometals; 2013 Jun; 26(3):387-402. PubMed ID: 23543383
[TBL] [Abstract][Full Text] [Related]
19. Transferrin serves as a mediator to deliver organometallic ruthenium(II) anticancer complexes into cells.
Guo W; Zheng W; Luo Q; Li X; Zhao Y; Xiong S; Wang F
Inorg Chem; 2013 May; 52(9):5328-38. PubMed ID: 23586415
[TBL] [Abstract][Full Text] [Related]
20. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
Ye S; Yang W; Wang Y; Ou W; Ma Q; Yu C; Ren J; Zhong G; Shi H; Yuan Z; Su X; Zhu W
Int J Mol Med; 2013 Jan; 31(1):33-42. PubMed ID: 23128378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
